ArticleEuropean journal of pediatrics2025
Evaluation of anti-HBs seropositivity rates in children with familial mediterranean fever.
Article in European journal of pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Reply to correspondence: functional immunity in hepatitis B: when titers don't tell the whole story.European journal of pediatrics · 2025Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to evaluate and compare anti-HBs seroprotection rates and antibody titers in pediatric familial Mediterranean fever (FMF) patients to healthy controls. This cross-sectional, single-center study included FMF patients followed at a tertiary pediatric rheumatology center between August 2016 and August 2024. Only patients who had received HBV vaccination according to the national vaccination schedule and had priorly documented anti-hepatitis B surface antibody (anti-HBs) titers were included. Anti-HBs levels > = 10 mIU/mL were considered seroprotective against HBV. A healthy control group, matched by age and gender with FMF patients included for comparison. FMF patients were categorized as colchicine-resistant and colchicine-responsive FMF patients. A total of 153 FMF patients and 158 healthy controls were included. FMF patients exhibited significantly lower anti-HBs seroprotection rates (46.4% vs. 58.2%; p = 0.037) and lower median anti-HBs titers (8.5 mIU/mL [IQR, 2-49.5] vs. 20.1 mIU/mL [IQR, 2-107.5]; p = 0.013) compared to healthy controls. Among FMF patients, males showed higher seroprotection rates (n = 44, 55.7%) compared to females (n = 27, 36.5%) (p = 0.017). In the FMF group, anti-HBs seroprotection rates declined with increasing age, from 75% in the youngest cohort (< 8 years) to 41.7% in adolescents (15-18 years) (p = 0.022). The seroprotective anti-HBs rate was significantly lower in colchicine-resistant FMF patients (n = 32, 45.1%) compared to the control group (n = 92, 58.2%) (p = 0.04). None of the patients tested positive for HBsAg, and no new HBV infections developed during a median follow-up of 67 months (IQR, 36-76). Conclusion: Children with FMF demonstrated lower anti-HBs titers and seroprotection rates compared to healthy controls. Colchicine resistance, older age, and female gender were associated with lower seroprotectivity. Serological screening for HBV immunity in FMF patients may help to guide individualized vaccination strategies. What is Known: • Hepatitis B vaccine-induced immunity may wane over time and patients with chronic inflammatory diseases may exhibit altered vaccine responses. What is New: • Anti-HBs seroprotection rates and antibody titers were significantly lower in children with familial Anti-HBs seroprotection rates and antibody titers were significantly lower in children with familial • Colchicine resistance, older age and female gender were associated with lower anti-HBs seroprotection rates among FMF patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.